Loading...
•
Dec 31, 2024
Third Harmonic Q4 2024 Earnings Report
Third Harmonic Bio reported a wider net loss in Q4 2024 as operating expenses rose, but maintained a strong cash position.
Key Takeaways
In Q4 2024, Third Harmonic Bio recorded no revenue and a net loss of $13.1 million or -$0.29 per share. The increase in expenses was driven by continued investment in the THB335 program. The company ended the quarter with $285.1 million in cash and cash equivalents and continues its strategic review process.
EPS was -$0.29, improving on expectations by $0.04.
Q4 net loss increased to $13.1 million from $6.8 million in Q4 2023.
R&D expenses rose to $10.5 million, reflecting investment in THB335.
Cash and cash equivalents stood at $285.1 million at quarter-end.
Third Harmonic
Third Harmonic
Forward Guidance
Third Harmonic Bio aims to initiate a Phase 2 trial for THB335 by mid-2025 and is exploring strategic alternatives to maximize value.
Positive Outlook
- Presented positive Phase 1 results for THB335.
- Preparing for 12-week placebo-controlled Phase 2 trial in CSU.
- Cash runway projected through at least 2026.
- Strong balance sheet with $285.1 million in cash.
- Focused pipeline with discontinued non-THB335 programs.
Challenges Ahead
- No product revenue reported in Q4 2024.
- Net loss widened year-over-year.
- R&D and G&A expenses continued to rise.
- Business still in pre-commercial phase with no approvals.
- Strategic review introduces operational uncertainty.